Toll Free: 1-888-928-9744

Compugen Ltd. - Product Pipeline Review - 2014

Published: Feb, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Compugen Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Compugen Ltd. - Product Pipeline Review - 2014', provides an overview of the Compugen Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Compugen Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Compugen Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Compugen Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Compugen Ltd.'s pipeline products

Reasons to buy

- Evaluate Compugen Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Compugen Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Compugen Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Compugen Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Compugen Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Compugen Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Compugen Ltd. Snapshot 6
Compugen Ltd. Overview 6
Key Information 6
Key Facts 6
Compugen Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Compugen Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Compugen Ltd. - Pipeline Products Glance 15
Compugen Ltd. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 17
Compugen Ltd. - Drug Profiles 18
CGEN-15001 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CGEN-15021 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CGEN-15031 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CGEN-15051 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CGEN-15091 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CGEN-25007 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CGEN-25008 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CGEN-25009 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CGEN-25068 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CGEN-856S 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CGEN-857 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Fusion Proteins For Autoimmune And Inflammatory Diseases 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibody Targeting CGEN-15001T For Cancer 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Monoclonal Antibody Targeting CGEN-15022 For Cancer 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody Targeting CGEN-671 For Epithelial Tumor 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody Targeting CGEN-928 For Multiple Myeloma 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Antibody Drug Conjugate Program 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody For Epithelial Cancers 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody Targeting CGEN-15049 For Cancer 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Compugen Ltd. - Pipeline Analysis 38
Compugen Ltd. - Pipeline Products by Target 38
Compugen Ltd. - Pipeline Products by Molecule Type 39
Compugen Ltd. - Pipeline Products by Mechanism of Action 40
Compugen Ltd. - Recent Pipeline Updates 41
Compugen Ltd. - Dormant Projects 44
Compugen Ltd. - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47
List of Tables
Compugen Ltd., Key Information 6
Compugen Ltd., Key Facts 6
Compugen Ltd. - Pipeline by Indication, 2014 9
Compugen Ltd. - Pipeline by Stage of Development, 2014 11
Compugen Ltd. - Monotherapy Products in Pipeline, 2014 12
Compugen Ltd. - Out-Licensed Products in Pipeline, 2014 13
Compugen Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
Compugen Ltd. - Preclinical, 2014 15
Compugen Ltd. - Discovery, 2014 17
Compugen Ltd. - Pipeline by Target, 2014 38
Compugen Ltd. - Pipeline by Molecule Type, 2014 39
Compugen Ltd. - Pipeline Products by Mechanism of Action, 2014 40
Compugen Ltd. - Recent Pipeline Updates, 2014 41
Compugen Ltd. - Dormant Developmental Projects,2014 44
Compugen Ltd., Subsidiaries 45 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify